WO2000061196A3 - Fatty acid analogs for diagnosis of coronary artery disease - Google Patents

Fatty acid analogs for diagnosis of coronary artery disease Download PDF

Info

Publication number
WO2000061196A3
WO2000061196A3 PCT/US2000/010096 US0010096W WO0061196A3 WO 2000061196 A3 WO2000061196 A3 WO 2000061196A3 US 0010096 W US0010096 W US 0010096W WO 0061196 A3 WO0061196 A3 WO 0061196A3
Authority
WO
WIPO (PCT)
Prior art keywords
diagnosis
fatty acid
coronary artery
artery disease
acid analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/010096
Other languages
French (fr)
Other versions
WO2000061196A2 (en
Inventor
John W Babich
Kevin Maresca
Timothy Shoup
Richard R Elmaleh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biostream Inc
Original Assignee
Biostream Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biostream Inc filed Critical Biostream Inc
Priority to DE60030270T priority Critical patent/DE60030270T2/en
Priority to JP2000610528A priority patent/JP2003517457A/en
Priority to EP00922209A priority patent/EP1173226B1/en
Priority to CA2366789A priority patent/CA2366789C/en
Priority to AU42433/00A priority patent/AU778834B2/en
Publication of WO2000061196A2 publication Critical patent/WO2000061196A2/en
Publication of WO2000061196A3 publication Critical patent/WO2000061196A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Fats And Perfumes (AREA)

Abstract

Radioimaging agents, which exhibit high uptake and retention in the myocardium are disclosed.
PCT/US2000/010096 1999-04-14 2000-04-14 Fatty acid analogs for diagnosis of coronary artery disease Ceased WO2000061196A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE60030270T DE60030270T2 (en) 1999-04-14 2000-04-14 FATTY ANALOGS FOR DIAGNOSIS OF CRANIAL AID DISORDERS
JP2000610528A JP2003517457A (en) 1999-04-14 2000-04-14 Fatty acid analogues for diagnosis of coronary artery disease
EP00922209A EP1173226B1 (en) 1999-04-14 2000-04-14 Fatty acid analogs for diagnosis of coronary artery disease
CA2366789A CA2366789C (en) 1999-04-14 2000-04-14 Fatty acid analogs for diagnosis of coronary artery disease
AU42433/00A AU778834B2 (en) 1999-04-14 2000-04-14 Fatty acid analogs for diagnosis of coronary artery disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12929899P 1999-04-14 1999-04-14
US60/129,298 1999-04-14

Publications (2)

Publication Number Publication Date
WO2000061196A2 WO2000061196A2 (en) 2000-10-19
WO2000061196A3 true WO2000061196A3 (en) 2001-07-26

Family

ID=22439338

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/010096 Ceased WO2000061196A2 (en) 1999-04-14 2000-04-14 Fatty acid analogs for diagnosis of coronary artery disease

Country Status (9)

Country Link
US (1) US6437103B1 (en)
EP (1) EP1173226B1 (en)
JP (1) JP2003517457A (en)
AT (1) ATE337020T1 (en)
AU (1) AU778834B2 (en)
CA (1) CA2366789C (en)
DE (1) DE60030270T2 (en)
ES (1) ES2269131T3 (en)
WO (1) WO2000061196A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE526995T1 (en) * 1995-12-01 2011-10-15 Molecular Insight Pharm Inc STEREOISOMERS OF FATTY ACID ANALOGUES FOR DIAGNOSTIC IMAGING
JP4846199B2 (en) * 2002-03-11 2011-12-28 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド Technetium-diviridine complex and method of use thereof
EP1490114A1 (en) * 2002-04-01 2004-12-29 Biostream, Inc. Pendant fatty acid imaging agents
CA2522737C (en) * 2003-04-17 2017-06-06 The General Hospital Corporation Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid
KR100533674B1 (en) * 2004-02-25 2005-12-06 한국원자력연구소 Method for preparing rhenium complex using borohydride exchange resin
WO2006131803A2 (en) * 2005-06-08 2006-12-14 Ge Healthcare Limited Method for the use of [11c] carbon monoxide in labeling synthesis of 11c-labelled esters and acids by sensitized photo-induced free radical carbonylation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524059A (en) * 1983-01-28 1985-06-18 The General Hospital Corporation Fatty acid analogs
US4615876A (en) * 1983-04-25 1986-10-07 Curators Of The University Of Missouri Macrocyclic complexes of technetium-99m for use as diagnostic radionuclides
US4746505A (en) * 1985-04-26 1988-05-24 President And Fellows Of Harvard College Technetium radiodiagnostic fatty acids derived from bisamide bisthiol ligands
WO1997019705A1 (en) * 1995-12-01 1997-06-05 Elmaleh David R Stereoisomers of fatty acid analogs for diagnostic imaging

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524059A (en) * 1983-01-28 1985-06-18 The General Hospital Corporation Fatty acid analogs
US4615876A (en) * 1983-04-25 1986-10-07 Curators Of The University Of Missouri Macrocyclic complexes of technetium-99m for use as diagnostic radionuclides
US4746505A (en) * 1985-04-26 1988-05-24 President And Fellows Of Harvard College Technetium radiodiagnostic fatty acids derived from bisamide bisthiol ligands
WO1997019705A1 (en) * 1995-12-01 1997-06-05 Elmaleh David R Stereoisomers of fatty acid analogs for diagnostic imaging

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ATSMA D. E. ET AL: "Potential of 99mTc-LDLs labeled by two different methods for scintigraphic detection of experimental atherosclerosis in rabbits", ARTERIOSCLEROSIS AND THROMBOSIS, vol. 13, no. 1, January 1993 (1993-01-01), pages 78 - 83, XP000981624 *
ELMALEH D. R.: "Myocardial imaging with 9-(Te-123m)telluraheptadecanoic acid", J NUCL. MED., vol. 22, 1981, pages 994 - 999, XP000979458 *
JONES G S ET AL: "7,10-bis(2-mercapto-2-methyl)propyl-7,10-diazapalmitic acid: a novel, N2S2 ligand for technetium-99m", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 6, no. 20, 22 October 1996 (1996-10-22), pages 2399 - 2404, XP004135846, ISSN: 0960-894X *
OKADA R. D.: "Tellurium-labeled fatty acid analogs: Relationship of heteroatom position to myocardial kinetics", EUR J. NUCL MED, vol. 11, 1985, pages 156 - 161, XP000981610 *
YAMAMURA N. ET AL: "Technetium-99m-labeled medium chain fatty acid analogues metabolized by b-oxidation: radiopharmaceutical for assesing liver function", BIOCONJUGATE CHEM, vol. 10, 16 April 1999 (1999-04-16), pages 489 - 495, XP002137894 *

Also Published As

Publication number Publication date
ES2269131T3 (en) 2007-04-01
US6437103B1 (en) 2002-08-20
AU4243300A (en) 2000-11-14
CA2366789A1 (en) 2000-10-19
CA2366789C (en) 2010-09-28
DE60030270D1 (en) 2006-10-05
EP1173226B1 (en) 2006-08-23
WO2000061196A2 (en) 2000-10-19
AU778834B2 (en) 2004-12-23
EP1173226A2 (en) 2002-01-23
JP2003517457A (en) 2003-05-27
ATE337020T1 (en) 2006-09-15
DE60030270T2 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
AP2003002731A0 (en) 6.alpha, 9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl) oxy!-11.beta.-hydroxy 16. alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl esters as an anti-inflammation agent
WO2001092283A3 (en) Cobalamin compounds useful as cardiovascular agents and as imaging agents
WO2004066805A3 (en) In vivo device for improving diastolic ventricular function
EE200200365A (en) Esters from (RR, SS) -3- (2-Dimethylaminomethyl-1-hydroxycyclohexyl) -phenyl-2-hydroxybenzoate
NO20003269L (en) Insoluble compositions for blood glucose control
WO2004091502A3 (en) 1,2,4-oxadiazole benzoic acid compounds
WO2000015174A3 (en) Bioflavonoid as blood glucose level lowering agent
AU3221599A (en) Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
WO2002040634A3 (en) Expression miniarrays and uses thereof
IT1309583B1 (en) PERFECTED CATHETER FOR VASCULAR INTERVENTIONS.
WO2004058185A3 (en) Antiangiogenesis by inhibiting protein kinase ck2 activity
WO2003010336A3 (en) Molecular markers for hepatocellular carcinoma
WO2001058476A3 (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
WO2005115233A3 (en) Differentiating ischemic from non-ischemic t-wave inversion
WO2000061196A3 (en) Fatty acid analogs for diagnosis of coronary artery disease
AU2001257406A1 (en) Methods and compositions for the diagnosis and treatment of cardiovascular and tumorigenic disease using 4941
DE69533876D1 (en) Composition for the gene therapy of coronary artery disease.
EP1123695A3 (en) Oral composition comprising capsules containing keratin
ZA200007437B (en) Composition for the oxidation dyeing of keratinous fibres comprising two particular quarternary polyammoniums.
CA2216004A1 (en) Improved rinse aid compositions containing phosphate esters
ATE441425T1 (en) CEREBROSPINAL AND VASCULAR PHARMACEUTICAL PREPARATION AND METHOD FOR THE PRODUCTION THEREOF
AU2001241778A1 (en) Methods and compositions for the diagnosis and treatment of cardiovascular, hepatic, and bone disease
WO2001046388A3 (en) Pathologically modified myocardial cell, production and use thereof
李陆平 et al. After the Dance——Selected from Jean and Johnny
WO2001048239A3 (en) Screening method for nucleic acids

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref document number: 2366789

Country of ref document: CA

Ref country code: CA

Ref document number: 2366789

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 610528

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000922209

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000922209

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2000922209

Country of ref document: EP